Quantum BioPharma's Unbuzzd Featured in Men's Fitness: Clinical Trial Shows Promise but Limitations

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse, was recently featured in a Men’s Fitness article by Lakshan Weeraratne that examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article, which highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults (24 completed both treatment sessions), reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. For Texas businesses and consumers, the coverage brings attention to a product that could potentially address alcohol recovery, a market with significant economic implications for the hospitality and wellness industries.

The Men’s Fitness article, however, emphasized the study’s limitations, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive. These caveats are important for readers to consider, as they underscore the need for further research before Unbuzzd can be widely adopted as a reliable recovery aid.

Quantum BioPharma retains ownership of 19.84% of Unbuzzd as of March 31, 2026, and the agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. This structure positions Quantum to benefit from Unbuzzd’s commercial success while maintaining flexibility for future pharmaceutical developments. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

The article’s publication in Men’s Fitness, a widely read fitness and lifestyle magazine, may increase consumer awareness of Unbuzzd and its potential benefits. For Texas, a state with a robust hospitality and tourism industry, products that claim to aid alcohol recovery could find a receptive market, particularly in urban centers like Austin, Dallas, and Houston. However, the mixed results and the need for independent validation mean that businesses should approach such products with cautious optimism. The full article is available at Men’s Fitness article by Lakshan Weeraratne, and the original release can be viewed at www.newmediawire.com. As the market for alcohol recovery products evolves, Quantum’s progress with Unbuzzd and its pipeline of drug candidates will be worth watching for investors and industry stakeholders alike.